Home›Trial›NCT07431398
NCT07431398Phase 1RECRUITING

Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

Study Summary

This clinical trial is a study to evaluate the pharmacokinetics of the tablet formulation Pociredir in fasted and fed state participants with Sickle Cell Disease (SCD).

Conditions
Sickle Cell Disease
Interventions / Drugs
Pociredir
View on ClinicalTrials.gov ↗
Sponsor
FULC
Fulcrum Therapeutics
Genetic Medicines
D44/100
Study Details
Enrollment24 participants
Primary Completion—
Lead SponsorFulcrum Therapeutics
Data Retrieved2026-04-11 04:14:15.292980+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 24 participants
Sponsor Catalyst Profile

Fulcrum Therapeutics (FULC) is the sponsoring company for this trial. BiotechSign currently grades this company D (44/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

FULC Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.